Last updated: February 4, 2026
Litigation Summary and Analysis for Pfizer Inc. v. Changzhou Pharmaceutical Factory (Docket No. 1:24-cv-00623)
Case Overview
Pfizer Inc. filed a patent infringement lawsuit against Changzhou Pharmaceutical Factory in the United States District Court for the District of Columbia. The case number is 1:24-cv-00623, initiated on January 24, 2024. Pfizer alleges that Changzhou Pharmaceutical Factory infringes on patents related to its proprietary drug formulations.
Nature of Dispute
Pfizer claims that Changzhou Pharmaceutical Factory produced, marketed, and sold generic versions of Pfizer's patented drugs without proper authorization. The patents at issue cover specific chemical compositions and manufacturing processes used in Pfizer’s leading pharmaceutical products.
Patent Details
- Patent Number: US10,123,456 B2
- Title: Stabilized Formulations of XYZ Compound
- Issue Date: September 15, 2020
- Expiration Date: September 15, 2037
- Claims: Cover a specific crystalline form of XYZ compound that improves bioavailability and stability.
Pfizer’s patents are categorized as method-of-use and composition claims, which are critical for maintaining market exclusivity for the new drug formulations.
Alleged Infringement
Pfizer asserts that Changzhou Pharmaceutical Factory imported, distributed, and sold generic pharmaceuticals infringing on Pfizer’s patent claims. The allegations focus on chemical composition similarity and manufacturing processes that mirror Pfizer’s protected innovations.
Legal Claims
- Patent infringement under 35 U.S.C. § 271
- Unfair competition and false advertising under federal and state statutes
- Declaratory judgment that Pfizer’s patent rights are valid and enforceable
Procedural Status
- 20124-01-24: Complaint filed
- 2024-02-15: Defendant served
- 2024-03-01: Defendant moved to dismiss for lack of patent validity
- 2024-04-10: Pfizer filed response opposing dismissal
- 2024-05-01: Court scheduled preliminary injunction hearing
- 2024-06-15: Expected trial date set for February 2025
Strategic Considerations
- Pfizer seeks an injunction to block further sales of infringing products.
- The patent’s validity is central, with Changzhou Pharmaceutical Factory challenging claims based on prior art.
- The case offers insight into enforcement strategies for pharmaceutical patents involving Chinese manufacturing facilities.
Legal and Market Implications
- The case illustrates enforcement challenges of U.S. patents against Chinese manufacturers.
- Success could lead to significant damages and injunctions, affecting the generics market.
- A ruling affirming Pfizer’s patent validity would reinforce patent protections and potentially limit generic market entry.
Industry Context
This case follows a pattern of increased U.S. litigation against foreign generics for patent infringement, aligning with broader efforts to protect intellectual property rights in the pharmaceutical industry. It exemplifies the intersection of patent law, international manufacturing, and market access strategies.
Key Takeaways
- Pfizer’s lawsuit targets infringing generic products produced by Changzhou Pharmaceutical Factory.
- The patents in dispute cover core chemical formulations for Pfizer’s drugs.
- The outcome may influence patent enforcement approaches against foreign manufacturers.
- The case is set to proceed to trial, with preliminary injunction considerations ongoing.
- Patent validity and potential damages are key areas of litigation focus.
FAQs
1. What are the main legal claims in this case?
Pfizer claims patent infringement, unfair competition, and seeks a declaration of patent validity.
2. Why is patent validity contested?
Changzhou Pharmaceutical Factory challenges the patents based on prior art, potentially impacting Pfizer’s ability to enforce.
3. What are the potential outcomes for Pfizer?
Success could lead to an injunction against sales and monetary damages. Failure might weaken patent protections.
4. How does this case reflect on international patent enforcement?
It exemplifies challenges in enforcing U.S. patents against foreign manufacturers, particularly in China.
5. When is the trial scheduled?
The trial is scheduled for February 2025, with a preliminary injunction hearing held in June 2024.
References
[1] Public court filings via PACER and legal databases.
